Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T...

Full description

Bibliographic Details
Published in:Cardiovascular Diabetology
Main Authors: David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund
Format: Article
Language:English
Published: BMC 2024-07-01
Subjects:
Diabetes mellitus
Type 2
Myocardial infarction
Sodium-glucose transporter 2 inhibitors
Online Access:https://doi.org/10.1186/s12933-024-02328-6

Internet

https://doi.org/10.1186/s12933-024-02328-6

Similar Items